Unified Protocol for Treatment of Emotional Disorders in Brief Groups in Primary Care Services in Spain

November 6, 2026 updated by: Jorge Javier Osma López, Instituto de Investigación Sanitaria Aragón

Study of the Cost-efficacy and Acceptability of the Unified Protocol for Treatment of Emotional Disorders in Brief Groups in Primary Care Services in Spain (PU-AP)

The aim of this project is to contribute to the improvement of psychological care received in primary care (PC), through the study of the cost-effectiveness and acceptability of the Unified Protocol for the treatment of emotional disorders in brief groups in primary care services in Spain (PU-AP) for the treatment of emotional disorders (EDs), the most prevalent in our society. To do so, a pilot study will be carried out, and, subsequently, a randomized clinical trial to study the efficacy, cost-effectiveness and acceptability of the Unified Protocol for the transdiagnostic treatment of EDs, applied in 5 or 8 group sessions. Finally, the researchers will analyze whether there are specific patient profiles that will benefit more from one or the other condition. The results will contribute to the personalization of the psychological treatment of users with EDs attending PC in the Spanish public health system.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Emotional disorders (EDs;including anxiety disorders, unipolar mood disorders, and related disorders) are the most prevalent mental disorders in the general population. In Spain, anxiety disorders and mood disorders affect approximately two million (4.1%) and two and half million (5.2%) individuals, respectively. As a result of their prevalence in the society, EDs have become an alarming health problem due to their associate costs. These disorders have a direct cost of 22.000 million euros (500 euros per capita and year). The total expense of these disorders entails 2.2% of the Gross Domestic Product in Spain.

In recent years, several alternatives have been proposed to address this situation, one of them being an increase in the number of clinical psychologists in our national health system (NHS) and, especially, their incorporation into primary care (PC) services.

It is considered that the incorporation of psychology in PC will help to reduce referral to specialized care because it will be possible to carry out a more exhaustive screening and determine which cases do not require psychological treatment, which cases should be referred to other health care resources and which cases can be treated in PC, usually mild-moderate TE. Another alternative to mitigate the excessive demand for care, regardless of the level of care, is the use of group psychological interventions, a cost-effective format for systems with limited resources such as our NHS.

Transdiagnostic interventions, like the Unified Protocol for the Treatment of EDs (UP), in brief group format, has emerged as a viable option for treating EDs in PC services.

The aim of the present study is to analyze the cost-effectiveness and acceptability of the Unified Protocol for the transdiagnostic treatment of EDs, applied in 5 or 8 group sessions.

Furthermore, it will try to find out which characteristics of the participants (e.g., gender, clinical diagnoses, transdiagnostic dimensions affected, symptom severity) predict a better outcome (e.g., clinical improvement and quality of life) as a function of the sessions received. Thus, in the future, it will be possible to offer the optimal number of sessions according to specific profiles (personalization of treatments).

Study Type

Interventional

Enrollment (Estimated)

180

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Jorge Osma, Ph.D
  • Phone Number: 978645390
  • Email: osma@unizar.es

Study Locations

    • Castellón
      • Vinaròs, Castellón, Spain, 12500
        • Recruiting
        • Hospital Comarcal de Vinaròs
        • Contact:
          • Vanessa Ferreres
    • Valencia
      • Villarreal, Valencia, Spain, 12540
        • Recruiting
        • Centro de Salud Carinyena, Hospital Universitario de La Plana
        • Contact:
          • Laura Camacho

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Have at least one EDs diagnosis (anxiety, depressive, obsessive-compulsive, trauma and somatic disorders) from the ADIS-5 interview
  • Have a score between 0 and 5 severity (mild-moderate) on the diagnoses on the CSR of the ADIS-5
  • Be able to attend all assessment and treatment sessions
  • Individuals on pharmacological treatment will be asked to maintain the dosage for the duration of the study, unless there is a medical contraindication

Exclusion Criteria:

  • Absence of clinical diagnosis
  • Presenting a diagnosis of EDs with a severity score on diagnoses between 6 and 8 on the ADIS-5 CSR (severe) or a clinical condition requiring specialized mental health intervention such as presence of severe mental disorder (e.g., personality disorder, bipolar disorder, or schizophrenia), suicide risk at the time of assessment, or substance use in the past three months
  • Who have received 8 or more sessions of CBT (during the past five years) with techniques such as cognitive flexibility or exposure
  • Who are receiving psychological treatment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 5-session UP condition

In both conditions, the contents of the UP manual were worked following the 2nd edition of the UP manual (Barlow et al., 2018). In the 5-session version, Module 1 (Motivation for Change and Commitment to Treatment) was removed, and Modules 6 and 7 (Interoceptive and Emotional Exposure) were combined. The content of Module 8 (Achievement, Maintenance, and Relapse Prevention) was addressed during the follow-up session. The sessions were conducted in groups, lasted 2 hours each, and were held weekly.

Unified Protocol (UP) for transdiagnostic treatment of EDs in 5-session

Active Comparator: 8-session UP condition

In both conditions, the contents of the UP manual were worked following the 2nd edition of the UP manual (Barlow et al., 2018). In the 8-session UP condition, each of the original 8 treatment modules was covered weekly. Module 7 (Emotional Exposure) was delivered across two sessions. The content of Module 8 (Achievement, Maintenance, and Relapse Prevention) was addressed during the follow-up session. The sessions were conducted in groups, lasted 2 hours each, and were held weekly.

Unified Protocol (UP) for transdiagnostic treatment of EDs in 8-session

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS-V)
Time Frame: Enrollment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.

Diagnostic interview

Diagnostic interview

Enrollment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.

The PHQ-9 (Patient Health Questionnaire-9) assesses depressive symptoms over the past two weeks using a 9-item scale. Each item is scored from 0 to 3, where 0 = "Not at all" and 3 = "Nearly every day". The total score range is 0-27, and is obtained by summing all item scores. Higher scores indicate more severe depressive symptoms.

Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Overall Depression Severity and Impairment Scale (ODSIS)
Time Frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.

Consist of five items that evaluate the frequency and the intensity of depressive symptoms and their interference with the person's work or school life and social life. The total score range from 0 to 20 and responses use a 5-point Likert scale ranging from 0 to 4.

Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Generalized Anxiety Disorder (GAD-7)
Time Frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.

The GAD-7 questionnaire assesses the presence of Generalized Anxiety Disorder (GAD), as listed in the DSM-V. The scale is composed by 7 items. Scores for all 7 items range from 0 (Not at all) and 3 (Nearly every day). Therefore, the total score ranges from 0 and 21. The total score may be categorized into four severity groups: minimal (0-4), mild (5-9), moderate (10-14) and serious (14-20)

Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Overall Anxiety Severity and Impairment Scale (OASIS)
Time Frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.

The scale presents five items. These items are related with the frequency and intensity of anxiety symptoms and their interference with the person's work or school life and with social life. All items are rated on a 5-point Likert scale ranging from 0 (I didn't feel anxious) to 4 (Constant anxiety).

Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
The World Health Organization-Five Well-Being Index (WHO-5)
Time Frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.

Is a self-report instrument measuring mental well-being. It consists of five statements relating to the past two weeks. Each statement is rated on a 6-point scale, with higher scores indicating better mental well-being.

Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Difficulties in Emotion Regulation Scale (DERS)
Time Frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.

Consists of 36-item of six facets of emotion regulation. Items are rated on a scale of 1 ("almost never [0-10%]") to 5 ("almost always [91-100%]"). Higher scores indicate more difficulty in emotion regulation

Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Multidimensional Emotional Disorder Inventory (MEDI)
Time Frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.

A self-report measure that includes only 49 items and enables to quickly assess the main transdiagnostic dimensions of Emotional disorders: neurotic temperament (MEDI_NT), positive temperament (MEDI_PT), depressed mood (MEDI_DM), autonomic arousal (MEDI_AA), somatic anxiety (MEDI_SOM), intrusive cognitions (MEDI_IC), social concerns (MEDI_SOC), traumatic re-experiencing (MEDI_TRM), and avoidance (MEDI_AVD). It uses a 9-point Likert-type response scale (0 = Does not characterize me; 8 = Totally characterizes me).

Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Working Alliance Inventory-Short (WAI-S)
Time Frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.

Evaluate the therapeutic or working alliance through 12 items grouped in three dimensions, called task (1, 2, 10 and 12), links (3, 5, 7 and 9) and objectives (4, 6, 8 and 11) measured through a Likert-type scale with scores ranging from 1 = Never to 7 = Always.

Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Maladjustment Scale (MI)
Time Frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.

Evaluates interference in different vital areas through six items with a 6-point Likert-type response scale (0 = Not at all; 5 = Extremely).

Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Adaptation of Client Satisfaction Questionnaire [CSQ-8]
Time Frame: At the end of treatment (approximately 5 or 8 weeks after enrollment), and 1-, 3-, and 6-month follow-ups after treatment completion.

An adaptation of 13 items that measures quality of the intervention and its components, discomfort experienced during treatment through the following 7 questions with a 4-point Likert-type response scale (0 = nothing; 3 =very much): 1) How would you rate the quality of the treatment program you received?; 2) Did you find the kind of psychological intervention you were looking for?; 3) If a friend or family member needed similar help, would you recommend our treatment program?; 4) Has the content you have learned helped you cope more effectively with your problems?; 5) Overall, how satisfied are you with the treatment program you received?; 6) To what extent has this treatment program caused you discomfort?; 7) If you had to seek help again, would you choose a group treatment program?

At the end of treatment (approximately 5 or 8 weeks after enrollment), and 1-, 3-, and 6-month follow-ups after treatment completion.
Group Climate Questionnaire (GCQ-S)
Time Frame: During treatment (2nd session)

The GCQ-S (Group Climate Questionnaire - Short) is a 12-item self-report measuring perceptions of the group's therapeutic environment, with each item rated 0-6 (total score 72). It has three subscales: Engagement (positive group atmosphere; higher scores = greater involvement), Conflict (tension and anger; higher scores = more interpersonal conflict), and Avoidance (withdrawal or evasion of responsibility; higher scores = more disengagement).

During treatment (2nd session)
Quality-adjusted Life Years (QALYs)
Time Frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.

Measure of disease burden, including both the quality and the quantity of life lived. It is used in economic evaluation to assess the value of medical interventions.

Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Work and Social Adjustment Scale (WSAS)
Time Frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.

The Work and Social Adjustment Scale (WSAS) identifies problems that affect an individual's ability to carry out everyday tasks. It consists of 5 items, each rated on a scale from 0 (Not at all) to 8 (Very severely). The total score is obtained by summing the ratings for all items, with a maximum possible score of 40. A WSAS score above 20 typically indicates moderately severe or worse psychopathology, while scores between 10 and 20 are associated with significant functional impairment but less severe clinical symptoms.

Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Client Service Receipt Inventory (CSRI)
Time Frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.

The Client Service Receipt Inventory (CSRI) is a self-report questionnaire that collects information on service use, including health and social care, medication, and other support services. The number of items varies depending on the version and study context, but it typically includes around 50-60 items. It is designed to evaluate the type, frequency, and duration of services used by clients, which can be used to estimate the associated costs and resource utilization.

Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Jorge Osma, Ph.D, Instituto de Investigación Sanitaria de Aragón, Universidad de Zaragoza

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 10, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

September 1, 2027

Study Registration Dates

First Submitted

August 7, 2024

First Submitted That Met QC Criteria

August 7, 2024

First Posted (Actual)

August 9, 2024

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 6, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • PID2023-151473OB-100

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Under request

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.